NCT03797456已完成2 期
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 32
- 主要终点
- Overall Response Rate (ORR)
研究概览
简要总结
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 110 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women between 18 and 75 years old
- •Histologically confirmed marginal zone lymphoma (MZL), and at least one measurable tumor of greater than 1.5 centimeter outside of the spleen
- •Subjects with refractory or relapsed MZL who has received at least 1 but no more than 4 prior therapies for MZL
- •ECOG performance status of 0-2
- •Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen
- •Subjects who have indications for treatment (threatened end-organ function, bulky disease >5cm, symptoms, steady progression, wish to treat)
- •Subjects meet the following laboratory parameters:
- •Absolute neutrophil count (ANC) ≥ 1.5×109/L Platelet count ≥ 75×109/L, independent of growth factor support within 7 days of the first dose with study drug, Hemoglobin ≥ 75 g/L; ANC ≥ 1.0×109/L, Platelet count ≥ 50×109/L, Hemoglobin ≥ 50 g/L; if bone marrow involvement
- •Total bilirubin ≤ 1.5× ULN; AST or ALT ≤ 2× ULN; Creatinine ≤ 1.5× ULN; Amylase ≤ ULN and Lipase ≤ ULN
- •International normalized ratio (INR) ≤ 1.5 ULN
- •Life expectancy ≥ 3 months
- •Able to provide signed written informed consent
排除标准
- •History of other active malignancies within 5 years of study entry, unless cured without evidence of relapse or metastasis
- •Current or history of lymphoma involved central nervous system
- •Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody-based therapies or anti-cancer TCM within 4 weeks of the start of study drug
- •Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy (except for alopecia)
- •Current clinically significant cardiovascular disease including:
- •Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%
- •Primary cardiomyopathy
- •Clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
- •Uncontrolled hypertension
- •Known active bleeding within 2 months of screening or currently taking anticoagulant/antiplatelet drugs
- •Urine protein ≥ 2+ and quantitation ≥ 2g/24hours
- •History of deep vein thrombosis or pulmonary embolism
- •Toxicity must be recovered to ≤ Grade 1 from prior anti-cancer therapy
- •Disease significantly affecting gastrointestinal function such as dysphagia, chronic diarrhea, intestinal obstruction, or resection of the stomach
- •Prior organ or hematopoietic stem cell transplant
- •Major surgery within 6 weeks of screening, except for diagnostic test or vascular access setup
- •Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
- •Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe lung function impairment
- •Prior exposure to a BTK or BCR pathway inhibitor (PI3K or Syk) and BCL-2 inhibitor
- •Suitable and ready for allogeneic stem cell transplant
- •Inability to comply with study procedures
- •Drug abuser or alcoholics
- •Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children
- •Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers.
研究组 & 干预措施
ICP-022
Experimental
干预措施: ICP-022 (Drug)
结局指标
主要结局
Overall Response Rate (ORR)
时间窗: Up to 3 years
The efficacy measured by overall response rate (ORR) in Part II according to the 2014 International Working Group NHL
次要结局
- Maximum plasma drug concentrations (Cmax)(up to 4 weeks)
- Duration of Response (DR)(Up to 3 years)
- Time of maximum plasma drug concentrations (Tmax)(up to 4 weeks)
- Progressioin free survival (PFS)(Up to 3 years)
- Area under the concentration time curve up to the time "t" (AUC(0-t))(up to 4 weeks)
- Area under the concentration time curve up to the last data point above LOQ (AUC(last))(up to 4 weeks)
- Overall survival (OS)(Up to 3 years)
- Occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I(Up to 3 years)
- Apparent half-life for designated elimination phases (t½)(up to 4 weeks)
研究者
研究点 (32)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)Mantle Cell LymphomaNCT03494179Beijing InnoCare Pharma Tech Co., Ltd.106
进行中（未招募）
2 期
A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLSecondary Central Nervous System LymphomaPCNSLNCT04438044Beijing InnoCare Pharma Tech Co., Ltd.61
尚未招募
2 期
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid TumorsAdvanced Solid TumorsNCT06704828Shanghai Hengrui Pharmaceutical Co., Ltd.20
撤回
不适用
Evaluation of Ciprofloxacin for Inhalation to Cystic Fibrosis Patients With P. AeruginosaCystic FibrosisNCT01090908Aradigm Corporation
撤回
1 期
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung DiseaseLung DiseasePulmonary DiseaseAlpha-1 Antitrypsin Deficiency-associated Lung DiseaseAATDAlpha-1 Antitrypsin DeficiencyNCT06622668Intellia Therapeutics30